150 related articles for article (PubMed ID: 18303124)
1. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.
Antila S; Pesonen U; Lehtonen L; Tapanainen P; Nikkanen H; Vaahtera K; Scheinin H
Eur J Pharm Sci; 2004 Nov; 23(3):213-22. PubMed ID: 15489122
[TBL] [Abstract][Full Text] [Related]
3. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
Antila S; Kivikko M; Lehtonen L; Eha J; Heikkilä A; Pohjanjousi P; Pentikäinen PJ
Br J Clin Pharmacol; 2004 Apr; 57(4):412-5. PubMed ID: 15025738
[TBL] [Abstract][Full Text] [Related]
5. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men.
Puttonen J; Laine T; Ramela M; Häkkinen S; Zhang W; Pradhan R; Pentikäinen P; Koskinen M
Eur J Pharm Sci; 2007 Dec; 32(4-5):271-7. PubMed ID: 17888637
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
8. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol.
Antila S; Järvinen A; Akkila J; Honkanen T; Karlsson M; Lehtonen L
Arzneimittelforschung; 1997 Jul; 47(7):816-20. PubMed ID: 9272237
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study.
Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
J Clin Pharmacol; 2004 Oct; 44(10):1143-50. PubMed ID: 15342615
[TBL] [Abstract][Full Text] [Related]
10. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment.
Kovarik JM; Sabia HD; Figueiredo J; Zimmermann H; Reynolds C; Dilzer SC; Lasseter K; Rordorf C
Clin Pharmacol Ther; 2001 Nov; 70(5):425-30. PubMed ID: 11719728
[TBL] [Abstract][Full Text] [Related]
11. The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.
Vachharajani NN; Shyu WC; Garnett WR; Morgenthien EA; Barbhaiya RH
Clin Pharmacol Ther; 1996 Sep; 60(3):283-94. PubMed ID: 8841151
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure.
Sandell EP; Hayha M; Antila S; Heikkinen P; Ottoila P; Lehtonen LA; Pentikainen PJ
J Cardiovasc Pharmacol; 1995; 26 Suppl 1():S57-62. PubMed ID: 8907132
[TBL] [Abstract][Full Text] [Related]
13. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment.
Bramson C; Ouellet D; Roman D; Randinitis E; Gardner MJ
J Clin Pharmacol; 2006 Jan; 46(1):29-36. PubMed ID: 16397281
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.
Small DS; Farid NA; Li YG; Ernest CS; Winters KJ; Salazar DE; Payne CD
J Clin Pharm Ther; 2009 Oct; 34(5):575-83. PubMed ID: 19744013
[TBL] [Abstract][Full Text] [Related]
15. Levosimendan: beyond its simple inotropic effect in heart failure.
Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
[TBL] [Abstract][Full Text] [Related]
16. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of levosimendan in clinical practice.
Silva-Cardoso J; Ferreira J; Oliveira-Soares A; Martins-de-Campos J; Fonseca C; Lousada N; Ilídio-Moreira J; Rabaçal C; Damasceno A; Amorim S; Seabra-Gomes R; Ferreira R; Abreu-Lima C;
Rev Port Cardiol; 2009 Feb; 28(2):143-54. PubMed ID: 19438150
[TBL] [Abstract][Full Text] [Related]
18. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
Abdallah H; Jerling M
J Clin Pharmacol; 2005 Jul; 45(7):802-9. PubMed ID: 15951470
[TBL] [Abstract][Full Text] [Related]
19. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
